Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Change in the Fiskars Group Leadership Team

Fiskars CorporationStock Exchange releaseOctober 3, 2024 at 12.00 p.m. EEST Change in the Fiskars Group Leadership Team Peter Holmberg, Chief Digital Officer and member of the Fiskars Group Leadership Team, has decided to leave Fiskars Group to join a new employer outside the company. He will step down from his role at Fiskars Group this week. Transition planning has already been started. “During his time in Fiskars Group, Peter has led us on a true digital transformation journey. I want to sincerely thank him for his many contributions to the company, including developing our

Vermiculus selected to deliver microservice-based CSD system to The Bermuda Stock Exchange

STOCKHOLM, October 3 2024, Vermiculus Financial Technology, a global provider of trading, clearing, and CSD technology, today announced it has been selected to deliver microservice-based clearing, settlement and depository (CSD) system to The Bermuda Stock Exchange (BSX), a wholly owned subsidiary of Miami International Holdings, Inc. The new BSX CSD systems are based on Vermiculus’ VeriClear™, an elastically scalable real-time product solution ensuring the highest possible performance as well as seamless integration with surrounding systems due to its modern and unique microservice-

Nomination Committee for Eastnine’s Annual General Meeting 2025

The members of Eastnine’s Nomination Committee for the Annual General Meeting 2025 have been appointed. The Nomination Committee comprises Anna Elam representing East Capital Holding and Peter Elam Håkansson, Erik Haegerstrand representing Bonnier Fastigheter Invest and Martin Zetterström representing Arbona, in addition to Liselotte Hjorth in her role as Chairman of the Board of Directors of Eastnine.The members of the Nomination Committee have been appointed based on the ownership structure as of 31 August 2024, with Liselotte Hjorth as convening. The Nomination Committee of Eastnine is

Swedavia’s traffic statistics for September 2024: More passengers and a focus on consolidating domestic traffic at Arlanda

During September, air travel at Swedavia's ten airports increased by two per cent compared with September 2023. This increase was driven by continued strong demand for international travel. International travel increased by four per cent, while domestic travel decreased by three per cent. At several regional airports, including Kiruna and Ronneby, domestic travel had a positive development during the month. Arlanda and Landvetter had the strongest trend for international traffic, with increases of six per cent and five per cent, respectively."Investments in efficient travel via Stockholm

Invitation to press and analyst conference

Holmen’s interim report for January–September 2024 will be published at 07.30 CEST on Thursday 24 October. In view of this, you are invited to watch the online broadcast of our press and analyst conference on the same day at 09.30 CEST. Time: 24 October at 09.30 CESTOnline broadcast: www.holmen.com/reports Holmen President and CEO Henrik Sjölund, together with CFO Anders Jernhall, will present and comment on the report. The presentation will be held in English. You may also participate in the conference by telephone, by calling: +46 8 505 100 31 (within Sweden)+44 207 107 06

Risk Intelligence A/S Extraordinary General Meeting 2024

Risk Intelligence A/S (“Risk Intelligence”) hereby calls an Extraordinary General Meeting.To the shareholders of Risk Intelligence A/S   NOTICE of Extraordinary General Meeting in Risk Intelligence A/S (CVR-nr. 27 47 56 71)     With reference to clause 5 of the Articles of Association of Risk Intelligence A/S (CVR-no. 27 47 56 71) and the Danish Companies Act, section 94, you are informed that an extraordinary general meeting is held;   Friday, 25 October 2024, at 10am at the Company’s address Strandvejen 100 DK-2900 Hellerup.    Participation

atNorth Announce New Operations Director for Denmark

Jeff Kjeldsen will lead the operations team across atNorth’s data centers in Denmark.Copenhagen, Denmark, October 3[rd], 2024 –  atNorth,  the leading Nordic colocation, high-performance computing, and artificial intelligence service provider, has announced the appointment of Jeff Kjeldsen as Operations Director for Denmark - a pivotal role following the recent announcement of atNorth’s second data center in Denmark and largest site to date – DEN02 . Jeff has a

Flex LNG finalize $430 million in new financings

Hamilton, BermudaOctober 3, 2024   Flex LNG Ltd (“Flex LNG” and/or the “Company”) (NYSE/OSE: FLNG) is pleased to announce today that the aggregate $430 million of new financings announced in the Q2-2024 report have been completed according to plan with net proceeds of about $97 million.   On September 24, 2024, the new $270 million bank facility financing Flex Aurora and Flex Ranger was completed, and the previous $375 million bank facility was repaid in full. Consequently, the Flex Endeavour was unencumbered at end of Q3-2024.     On October 3, 2024, the Company

Saniona’s CEO to BioStock: “SAN2355 is a highly promising candidate for commercialization”

Saniona has announced significant progress in the preclinical development of the epilepsy drug candidate SAN2355 to treat focal-onset seizures. BioStock talked to CEO Thomas Feldthus to learn more.Read the full interview with Thomas Feldthus at biostock.se: https://www.biostock.se/en/2024/10/sanionas-ceo-san2355-is-a-highly-promising-candidate-for-commercialization/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Belatra Releases Explosive Lucky Bandits Slot

Belatra Games, the specialist online slots developer, has released its latest hot shot, Lucky Bandits. This exhilarating escapade launches players into the lawless lands of the Wild West that are brought to life with stunning visuals, immersive soundscapes, and thrilling gameplay.The game is bursting with engaging features such as Free Games, Hot Mode, and the intense Shot and Dynamite Bonuses. Players can also instantly jump into the action with the Buy Bonus feature, avoiding the wait for naturally triggered rewards. Free Games are at the heart of the game, triggered when three or more

Q3 2024 Trading Update

In Q3 2024, the harvest volumes for Bakkafrost’s operation in the Faroe Islands and Scotland were: · Faroe Islands:   21.6 thousand tonnes · Scotland:         5.4 thousand tonnes All harvest volumes are provided in head-on gutted (HOG) equivalents. Feed sales in Q3 2024 were 41.5 thousand tonnes. Havsbrún sourced 40.0 thousand tonnes of raw materials in Q3 2024.  The full Q3 2024 report will be released on 5 November 2024 at 06:00 CET. Contacts: · Regin Jacobsen, CEO of P/F Bakkafrost: +298 23 50 01 (mobile) · Høgni Dahl Jakobsen, CFO of P/F Bakkafrost: +298 23

GiG Software P.L.C. - Notification of trade by Board Member Andreas Soneby

Andreas Soneby, a primary insider and Board Member of GiG Software P.L.C. (GiG) has acquired 30,000 Swedish Depository Receipts (SDR) in GiG at a price of SEK 4.60 per SDR. After this transaction, Andreas Soneby holds 30,000 SDRs in GiG.GiG Software P.L.C. - Notification of trade by Board Member Andreas Soneby   Andreas Soneby, a primary insider and Board Member of GiG Software P.L.C. (GiG) has acquired 30,000 Swedish Depository Receipts (SDR) in GiG at a price of SEK 4.60 per SDR. After this transaction, Andreas Soneby holds 30,000 SDRs in GiG.     For further information,

New study by Uute Scientific proves that microbial extract from Finnish nature helps patients with atopic dermatitis

Due to the modern lifestyle of extreme hygiene and lack of exposure to nature, immune-mediated diseases are on the rise globally. For the first time in history, results of the new study by researchers of Uute Scientific show that by spreading microbial extract on their skin, patients with atopic dermatitis need significantly less atopy medication.HELSINKI, Finland (October 3rd, 2024) – Finnish biotech startup Uute Scientific  has published a study on a new supporting treatment for atopic dermatitis based on natural microbial exposure. The study was conducted

NRC Group ASA: New share capital registered

Reference is made to the stock exchange announcement made by NRC Group ASA (the "Company") on 10 September 2024 regarding the successful completion of a private placement of 80,000,000 new shares (the "New Shares") at a subscription price of NOK 2.50 per share (the "Private Placement"). The share capital increase pertaining to the issuance of the New Shares has now been registered with the Norwegian Register of Business Enterprises. The Company's new registered share capital is NOK 152,954,549 divided on 152,954,549 shares, each with a nominal value of NOK 1.00. The New Shares will be

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 219 – 3 OCTOBER 2024   In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 171/24 and 173/24, respectively. Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Martin Badsted, Chief Financial Officer, tel.: +45 33 42 05 26, e-mail: mba@norden.com

Nomination Committee for Volvo Cars Annual General Meeting 2025 appointed

In line with the principles adopted by Volvo Cars' Annual General Meeting and based on the shareholder information as of August 30, 2024 the Nomination Committee for Volvo Cars' Annual General Meeting 2025 has been appointed and its members are: · Thomas Johnstone, appointed by Geely Sweden Holdings AB · Yimin Chen, appointed by Geely Sweden Holdings AB · Eric Li, Chairperson of the Board of Volvo Car AB · Anders Oscarsson, appointed by AMF as the second largest shareholder · Emilie Westholm, appointed by Folksam as the third largest shareholder The Nomination Committee

Recipharm strengthens pharmaceutical development capabilities with strategic investments

· New investments include expanded capabilities in Oral Solid Dosage (OSD), Sterile Fill & Finish (SFF) and complement existing development capabilities.  · New product development lab for sterile liquids and lyo products, as well as GMP pilot scale lines for BFS, PFS and vials. · Expanded labs and new GMP pilot scale equipment for product development. · Investment in analytical labs’ Extractables and Leachables, Nitrosamines and Elemental Impurities capabilities. · Group offering now covers all phases of product development, from API route scouting and synthesis, to commercial

Lindex wins Digital Initiative of the Year and Susanne Ehnbåge is named Leader of the Year

Lindex wins the Digital Initiative of the Year award, and Susanne Ehnbåge, Lindex’s CEO, is named Leader of the Year at the industry gala Retail Awards, organised by Swedish Commerce. The jury's motivations highlight how Lindex is breaking new ground with its innovative AI solution, Lindex Copilot, which supports employees in store, as well as how the fashion company, under Susanne Ehnbåge's leadership, has achieved impressive economic growth while significantly reducing its carbon footprint. ‘I am incredibly happy and honoured to receive this prestigious award. For me, it is not

Lundbeck initiates clinical trial in immunology for Lu AG22515 in Thyroid Eye Disease

H. Lundbeck A/S (Lundbeck) today announced taking one further step in developing treatments for indications in the neuroimmunology and neuroinflammatory space with the initiation of the first clinical trial of its CD40L blocker, Lu AG22515, in patients.Lundbeck’s proof-of-concept (PoC) trial will evaluate the efficacy, safety, and tolerability of Lu AG22515 as a potential treatment for Thyroid Eye Disease, an autoimmune disease causing a debilitating, disfiguring, and potentially blinding periocular condition. “We are excited to initiate our first project within neuroimmunology with this

Stora Enso prepares to sell parts of its forest assets in Sweden (Inside information)

STORA ENSO OYJ INSIDE INFORMATION 3 October 2024 at 10:00 EESTStora Enso is preparing to sell approximately 12% of its total forest assets of 1.4 million hectares in Sweden. Stora Enso has therefore initiated steps to implement a new legal structure for its Swedish forest assets to facilitate the potential sale. A potential transaction would be subject to agreeing terms and conditions with investors, including a long-term wood supply and forest management agreement. A sale would reduce debt and further strengthen Stora Enso’s balance sheet, confirming the financial value of the Company’s

BioStock: Cereno Scientific discusses phase IIa results for CS1

The trial was made with the company’s lead candidate, CS1, in the rare cardiovascular disease Pulmonary Arterial Hypertension. See Sten R Sörensen, CEO, announce the results and their impact on Cereno Scientific.See the interview at biostock.se:https://www.biostock.se/en/2024/10/cereno-scientific-discusses-phase-iia-results-for-cs1/This is a press release from BioStock - Connecting Innovation & Capital.

BioStock has published an article and interview with CEO Sten R. Sörensen on the positive topline results from Cereno Scientific’s Phase IIa trial on CS1 in PAH

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that BioStock has published an article and executive interview on the positive topline results from the Company’s Phase IIa trial on CS1 in rare disease Pulmonary Arterial Hypertension (PAH).In the article and interview, Cereno’s CEO Sten R. Sörensen comments on the results of the Phase IIa study in PAH as well as the importance of these new insights for the company and ultimately for patients suffering from PAH.   Read the full

BioStock: Cereno’s phase IIa results positive, clear path forward

Recently, Cereno Scientific announced positive topline results from the phase IIa trial of CS1 in pulmonary arterial hypertension. The results demonstrate that the candidate is safe, well tolerated, and has a positive impact on clinically relevant parameters. The phase IIa clinical trial data, together with preclinical information, are consistent with reversing pathological remodeling, which is in line with the development goals for CS1.Read the article about Cereno Scientific at biostock.se:  https://www.biostock.se/en/2024/10/cerenos-phase-iia-results-looks-promising 

There are no items matching the current filter
There are no more items matching the current filter
Back to top